Pamela Ruppel
Psychiatric/Mental Health · Roanoke, VANPI 1992868657
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,125 of the $20,705 with a category attached, or 73.0%. AbbVie accounts for 77.7% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $8,108 and has fallen 87.2% since, to $1,037 in 2025. Among psychiatric/mental health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 346 payments — averaging $59.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$16K
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$764
- Neurocrine Biosciences, Inc.$462
- Johnson & Johnson$342
- Otsuka America Pharmaceutical, Inc.$294
- plus $1K from 14 others
What the payments were for
- Speaking & faculty fees$15,12573%
- Food & beverage$5,10125%
- Education$4792%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 113 | $16,091 |
| Teva Pharmaceuticals USA, Inc. | 68 | $1,445 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 51 | $764 |
| Neurocrine Biosciences, Inc. | 23 | $462 |
| Johnson & Johnson | 13 | $342 |
| Otsuka America Pharmaceutical, Inc. | 21 | $294 |
| Corium, LLC | 12 | $188 |
| Lundbeck LLC | 8 | $162 |
| Vanda Pharmaceuticals Inc. | 7 | $139 |
| E.r. Squibb & Sons, L.L.C. | 3 | $131 |
| Novo Nordisk | 2 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $107 |
| Axsome Therapeutics, Inc. | 5 | $107 |
| Livanova USA, Inc. | 1 | $97 |
| Alkermes, Inc. | 5 | $73 |
| Idorsia Pharmaceuticals US Inc | 3 | $46 |
| Collegium Pharmaceutical, Inc. | 2 | $43 |
| Aimmune Therapeutics, Inc. | 1 | $33 |
| Noven Therapeutics, LLC | 2 | $30 |
| Ironshore Pharmaceuticals Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,705 in reported general payments places this provider in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 819 | $1,207,334 |
| IngrezzaValbenazine Tosylate | 23 | $195,279 |
| CaplytaLumateperone Tosylate | 24 | $38,009 |
| VraylarCariprazine Hcl | 12 | $31,572 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $19,970 |
| TrintellixVortioxetine Hydrobromide | 17 | $18,296 |
| VyvanseLisdexamfetamine Dimesylate | 23 | $10,536 |
| AzstarysSerdexmethylphen/Dexmethylphen | 20 | $7,878 |
| MydayisDextroamphetamine/Amphetamine | 14 | $4,683 |
| Eszopiclone | 17 | $3,101 |
| Lisdexamfetamine Dimesylate | 14 | $3,085 |
| Lurasidone Hcl | 19 | $2,494 |
| Bupropion XlBupropion Hcl | 51 | $1,898 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 18 | $1,867 |
| Temazepam | 20 | $1,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $342 | $1,207,334819 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $462 | $195,27923 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $764 | $38,00924 claims |
| AbbVieVraylar | $16,091 | $31,57212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $107 | $28,83240 claims |
| Axsome Therapeutics, Inc.Auvelity | $107 | $19,97018 claims |
| Corium, LLCAzstarys | $188 | $7,87820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Other psychiatric/mental health in Roanoke
- Tiffany ChailleRoanoke$6K
- Justin RayChesapeake$127K
- Katia HallChesapeake$88K
- Christine GilmoreBedford$75K
- Sarah FaberNewport News$59K
- Kristine GarciaGlen Allen$46K
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
- Juliana FroschAmherst$36K
- Derick ReedyNickelsville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.